Wire · operational-macro
FDA Approves Cemdisiran as New Treatment for Generalized Myasthenia Gravis
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 19 November 2026 · Fusion42 review
The FDA approved cemdisiran (Livsayis), a quarterly subcutaneous siRNA treatment targeting complement C5, for adults in the US with AChR-antibody-positive generalized myasthenia gravis (gMG). Supported by the phase 3 NIMBLE trial showing significant efficacy and safety, Livsayis is the first siRNA therapy and provides the least frequent dosing among complement-targeted gMG treatments.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You just gained access to a newly approved siRNA therapy with quarterly dosing that could redefine treatment convenience for AChR-antibody-positive generalized myasthenia gravis. Prepare to engage neurologists keen on alternatives to frequent infusion therapies and explore patient adherence benefits.
◆ Coverage
1 source · 19 Nov 2026
◆ Related on Wire
◆ Topics